 CytoDyn Inc shared an update to its previously reported preliminary results from its Phase 1b2 trials and compassionate use of its flagship drug candidate leronlimab to treat a total of 30 metastatic triple-negative breast cancer mTNBC patients. The Vancouver, Washington-based late-stage biotechnology company said that decrease in circulating tumor cells CTC as reported using the LifeTracDx test developed by Creatv MicroTech Inc, after induction with leronlimab was associated with a 400-to-660 increase in modified progression free Survival mPFS, 12-month Progression Free Survival PFS and a 570-to-980 increase in modified overall survival mOS, and 12-month overall survival. 